Screening for hormonal, monogenic, and syndromic disorders in obese infants and children

Pediatric Annals
|September 9, 2014
PubMed

Insights

Pediatric obesity in the US affects 17% of children. This review distinguishes common exogenous obesity from rarer endogenous causes, which involve hormonal, genetic, or syndromic disorders.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Genetics

Background:

  • Pediatric obesity prevalence in the US is nearly 17%.
  • Most cases are exogenous (excess energy intake vs. expenditure).
  • A subset of cases are endogenous, linked to hormonal, genetic, or syndromic disorders.

Purpose of the Study:

  • To review hormonal, monogenic, and syndromic causes of childhood obesity.
  • To identify critical features distinguishing endogenous from exogenous obesity.
  • To discuss laboratory testing and subspecialist referral for suspected endogenous obesity.

Main Methods:

  • Literature review of hormonal, genetic, and syndromic causes of pediatric obesity.
  • Analysis of clinical features suggestive of endogenous obesity.
  • Discussion of diagnostic approaches, including laboratory tests and referral criteria.

Main Results:

  • Endogenous obesity is associated with specific hormonal (e.g., hypothyroidism, Cushing's syndrome), genetic (e.g., leptin signaling defects, MC4R mutations), and syndromic (e.g., Prader-Willi, Bardet-Biedl) disorders.
  • Key indicators for endogenous obesity include infantile onset, lack of satiety, poor linear growth, dysmorphic features, and cognitive dysfunction.
  • Guidelines for laboratory testing and subspecialist referral are provided.

Conclusions:

  • Differentiating endogenous from exogenous pediatric obesity is crucial for appropriate management.
  • Specific clinical findings and diagnostic tests aid in identifying underlying causes of endogenous obesity.
  • Timely referral and targeted investigations are essential for children with suspected endogenous obesity.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
361
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
319
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
431